α1-adrenergic receptor subtypes in nonfailing and failing human myocardium

Circulation: Heart Failure

Volumn 2, Issue 6, 2009, Pages 654-663

  Jensen, Brian C ^a,b,c   Swigart, Philip M ^a   De Marco, Teresa ^b   Hoopes, Charles ^b   Simpson, Paul C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Adrenergic, beta; Heart failure; Myocardium; Receptors; Receptors, adrenergic, alpha

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; HYDRALAZINE; INSULIN; LEVOTHYROXINE; MILRINONE; NITRATE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; RECEPTOR SUBTYPE; SILDENAFIL; VASOPRESSIN;

ADULT; ARTICLE; DRUG TARGETING; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART GRAFT; HEART MUSCLE; HEART VENTRICLE; HUMAN; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 70049100780     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.846212     Document Type: Article

References (50)

1. Simpson PC. Lessons from knockouts: the alpha-1-ARs. In: Perez DM, ed. The Adrenergic Receptors in the 21st Century. Totowa, New Jersey: Humana Press; 2006:207-240.
2. O'Connell TD, Ishizaka S, Nakamura A, Swigart PM, Rodrigo MC, Simpson GL, Cotecchia S, Rokosh DG, Grossman W, Foster E, Simpson PC. The alpha (1A/C) - and alpha (1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. J Clin Invest. 2003;111:1783-1791.
3. O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, Tecott LH, Baker AJ, Foster E, Grossman W, Simpson PC. Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest. 2006;116:1005-1015.
4. Vecchione C, Fratta L, Rizzoni D, Notte A, Poulet R, Porteri E, Frati G, Guelfi D, Trimarco V, Mulvany MJ, Agabiti-Rosei E, Trimarco B, Cotecchia S, Lembo G. Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation. 2002;105:1700-1707.
5. Rodrigo MC, Joho S, Swigart PM, Foster E, O'Connell TD, Grossman W, Simpson PC. The alpha-1-B adrenergic receptor subtype is required for physiological cardiac hypertrophy in normal development (abstract). Circulation. 2005;112:II-123.
6. Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, O'Connell TD. An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation. 2007;115:763-772.
7. Rokosh DG, Simpson PC. Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA. 2002;99:9474-9479.
8. Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T, Sunada S, Takeo S, Tsujimoto G. The alpha (1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest. 2002;109:765-775.
9. Turnbull L, McCloskey DT, O'Connell TD, Simpson PC, Baker AJ. Alpha 1-adrenergic receptor responses in alpha 1AB-AR knockout mouse hearts suggest the presence of alpha 1D-AR. Am J Physiol Heart Circ Physiol. 2003;284:H1104-H1109.
10. Chalothorn D, McCune DF, Edelmann SE, Tobita K, Keller BB, Lasley RD, Perez DM, Tanoue A, Tsujimoto G, Post GR, Piascik MT. Differential cardiovascular regulatory activities of the alpha 1B-and alpha 1D-adrenoceptor subtypes. J Pharmacol Exp Ther. 2003;305: 1045-1053.
11. Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, Lefkowitz RJ. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA. 1994;91:10109-10113.
12. Akhter SA, Milano CA, Shotwell KF, Cho MC, Rockman HA, Lefkowitz RJ, Koch WJ. Transgenic mice with cardiac overexpression of alpha 1B-adrenergic receptors. In vivo alpha1-adrenergic receptormediated regulation of beta-adrenergic signaling. J Biol Chem. 1997; 272:21253-21259.
13. Lemire I, Ducharme A, Tardif JC, Poulin F, Jones LR, Allen BG, Hebert TE, Rindt H. Cardiac-directed overexpression of wild-type alpha1B-adrenergic receptor induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2001;281:H931-H938.
14. Zuscik MJ, Chalothorn D, Hellard D, Deighan C, McGee A, Daly CJ, Waugh DJ, Ross SA, Gaivin RJ, Morehead AJ, Thomas JD, Plow EF, McGrath JC, Piascik MT, Perez DM. Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor. J Biol Chem. 2001;276:13738-13743.
15. Lin F, Owens WA, Chen S, Stevens ME, Kesteven S, Arthur JF, Woodcock EA, Feneley MP, Graham RM. Targeted alpha (1A) - adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res. 2001;89:343-350.
16. Du XJ, Fang L, Gao XM, Kiriazis H, Feng X, Hotchkin E, Finch AM, Chaulet H, Graham RM. Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction. J Mol Cell Cardiol. 2004;37:979-987.
17. Du XJ, Gao XM, Kiriazis H, Moore XL, Ming Z, Su Y, Finch AM, Hannan RA, Dart AM, Graham RM. Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. Cardiovasc Res. 2006;71:735-743.
18. Rorabaugh BR, Ross SA, Gaivin RJ, Papay RS, McCune DF, Simpson PC, Perez DM. Alpha1A-but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrineinsensitive mechanism. Cardiovasc Res. 2005;65:436-445.
19. Chaulet H, Lin F, Guo J, Owens WA, Michalicek J, Kesteven SH, Guan Z, Prall OW, Mearns BM, Feneley MP, Steinberg SF, Graham RM. Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol. 2006;40:540-552.
20. Chan T, Dash R, Simpson PC. An alpha-1A-adrenergic receptor subtype agonist prevents cardiomyopathy without increasing blood pressure (abstract). Circulation. 2008;118:S533.
21. ALLHAT CRG. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). [see comments]. JAMA. 2000;283:1967-1975.
22. Cohn JN. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction. Circulation. 1993;87:VI1-4.
23. Scholz H, Eschenhagen T, Neumann J, Stein B. Receptor-mediated regulation of cardiac contractility: inotropic effects of alpha-adrenoceptor stimulation with phenylephrine and noradrenaline in failing human hearts. In: Endoh M, Morad M, Scholz H, Iijima T, eds. Molecular and Cellular Mechanisms of Cardiovascular Regulation. Tokyo: Springer-Verlag; 1996:317-325.
24. Skomedal T, Borthne K, Aass H, Geiran O, Osnes JB. Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther. 1997;280:721-729.
25. Cleveland JC Jr, Meldrum DR, Rowland RT, Cain BS, Meng X, Gamboni-Robertson F, Banerjee A, Harken AH. Ischemic preconditioning of human myocardium: protein kinase C mediates a permissive role for alpha 1-adrenoceptors. Am J Physiol. 1997;273:H902-H908.
26. Cleveland JC Jr, Wollmering MM, Meldrum DR, Rowland RT, Rehring TF, Sheridan BC, Harken AH, Banerjee A. Ischemic preconditioning in human and rat ventricle. Am J Physiol. 1996;271:H1786-H1794.
27. Loubani M, Galinanes M. Alpha1-adrenoceptors during simulated ischemia and reoxygenation of the human myocardium: effect of the dose and time of administration. J Thorac Cardiovasc Surg. 2001;122:103-112.
28. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002;105:1797-1803.
29. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-667.
30. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004;110:1437-1442.
31. Van Tassell BW, Rondina MT, Huggins F, Gilbert EM, Munger MA. Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. Am Heart J. 2008; 156:315-321.
32. Bohm M, Diet F, Feiler G, Kemkes B, Erdmann E. Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol. 1988;12:357-364.
33. Bristow MR, Minobe W, Rasmussen R, Hershberger RE, Hoffman BB. Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther. 1988;247:1039-1045.
34. Vago T, Bevilacqua M, Norbiato G, Baldi G, Chebat E, Bertora P, Baroldi G, Accinni R. Identification of alpha 1-adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein. Circ Res. 1989;64:474-481.
35. Jensen BC, Swigart PM, Laden ME, De Marco T, Hoopes C, Simpson PC. The alpha-1D is the predominant alpha-1 adrenergic receptor subtype in human epicardial coronary arteries. J Am Coll Cardiol. 2009;54: 1137-1145.
36. Faure C, Gouhier C, Langer SZ, Graham D. Quantification of alpha 1-adrenoceptor subtypes in human tissues by competitive RT-PCR analysis. Biochem Biophys Res Commun. 1995;213:935-943.
37. Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, Schwinn DA. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. Mol Pharmacol. 1994;45:171-175.
38. Tseng-Crank J, Kost T, Goetz A, Hazum S, Roberson KM, Haizlip J, Godinot N, Robertson CN, Saussy D. The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol. 1995;115:1475-1485.
39. Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M. Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994;201:1296-1304.
40. Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA. Subtype specific regulation of human vascular alpha (1) - adrenergic receptors by vessel bed and age. Circulation. 1999;100: 2336-2343.
41. Shannon R, Chaudhry M. Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006;152:842-850.
42. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
43. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.
44. Rokosh DG, Stewart AF, Chang KC, Bailey BA, Karliner JS, Camacho SA, Long CS, Simpson PC. Alpha1-adrenergic receptor subtype mRNAs are differentially regulated by alpha1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. Repression of alpha1B and alpha1D but induction of alpha1C. J Biol Chem. 1996;271: 5839-5843.
45. Goetz AS, King HK, Ward SD, True TA, Rimele TJ, Saussy DL Jr. BMY 7378 is a selective antagonist of the D subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1995;272:R5-R6.
46. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kuhl U, Schultheiss HP. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation. 1999;99:2750-2756.
47. Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation. 1991;83: 1866-1872.
48. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997;100: 2315-2324.
49. Jensen BC, Swigart PM, Simpson PC. Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol. 2009;379:409-412.
50. Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006;97:747-751; discussion 751.